technical analysis

Will this stock be in like a lion and out like a lamb?
Strength above $54 could mean CYBR is headed higher while weakness below $46 may indicate it will decline to the low $40s.
The stock is headed toward a bullish golden cross.
Technical indicators suggest GSK can see further significant gains in 2017.
Base building pays off.
An upside breakout appears on the horizon.
It now looks like APA bulls can go long again.
SNA has reached a juncture point.
The indexes are still mostly in short-term downtrends.
The bulls will need to prove themselves with this supplier of construction aggregates, which appears vulnerable to further declines.

Columnist Conversations

I have a special guest joining me today, legendary technician Marc Chaikin comes aboard tonight, talking about...
View Chart »  View in New Window » To fail or not to fail is the question.  The video I d...
I've been suspect of CSCO since early this month and am still convinced a pullback is on the way. The stock h...
I forgot to list my short positions in RH puts in my disclosure on retail shares. Paul


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.